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ABSTRACT 
 
Objective: The objective of this selective EBM review is to determine whether or not daily 
supplementation with omega-3 fatty acids is effective in reducing the severity of dry eyes in 
adult patients with dry eyes syndrome (DES). 
 
Methods: Three randomized controlled trials are included in this review that were published in 
2013, 2016 and 2017. 
 
Data sources: The author of this paper performed the research as well as selected the articles for 
review by conducting searches on PubMed, Embase and Cochrane Library. 
 
Outcomes: The outcome measured is the severity of dry eyes symptoms measured subjectively 
by each patient through a 12-item questionnaire after a minimum of one month and maximum 12 
weeks of treatment. The Ocular Surface Disease Index (OSDI), (Allergan, Inc.), scale was used 
to measure subjective outcomes in all studies. An average score for each group was calculated as 
well as the change in scores between the first and the last day of studies.1,2,3 
 
Results:  In Deinema et al (2017), for patients taking krill oil supplementation, dry eye 
symptoms improved 18.6+/-2.4 points (mean change in baseline score) over three months per 
OSDI scores.1 In Epitropoulo et al (2016), in the treatment group symptoms improved 17.0+/-2.6 
points over three months.2 In Kangari et al (2013), symptoms improved 9.4+/-0.6 points over one 
month patients receiving treatment while the placebo group reported a 1.2+/-0.3 point worsening 
of symptoms.3 All data described above was statistically significant (p < 0.005). 
 
Conclusions: It can be concluded that daily omega-3 essential fatty acid supplementation is 
effective for reducing the severity of dry eye syndrome in adults, especially those with mild-
moderate DES after 90 days. 
 
Key Words:  Dry eye syndrome; Omega-3 fatty acids 
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INTRODUCTION 
Dry eyes are a manifestation of a disorder that is best known as dry eye disease (DED)1, 
meibomian gland dysfunction (MGD)2 or dry eye syndrome (DES)3. This is a multifactorial 
disease of the lacrimal gland that involves an inflammatory response at the ocular surface with 
debilitating irritation as well as profound visual impairment.4 It occurs when the eye is not 
properly lubricated with tears as a result of either poor production, excessive evaporation or 
improperly balanced components.4  
This systematic review paper evaluates three randomized clinical trials (RCT’s) in order to 
compare the efficacy of daily supplementation with oral omega-3 (ω-3) fatty acids for reducing 
the severity of dry eyes in adult patients with DES. Earlier studies reported that intake of ω-3 
fatty acids, through dietary consumption of fish or by oral supplementation, have anti-
inflammatory effects within the body. This was first seen by a reduction of autoimmune disease 
incidence, and later on for the benefit of other disorders like DES.5 Current research suggests that 
omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) block pro-
inflammatory mediators at the surface of the eye while providing symptomatic relief.1,2,3 
Healthy eyes require protection from multiple layers of tears in order to function properly.6 
First, a lipid layer helps spread the tear film evenly over the surface. Next, an aqueous protein 
layer nourishes the cornea. Lastly, a mucous layer provides continuous lubrication.6 DES 
involves either the decreased production of tears (aqueous-deficiency) or increased evaporative 
loss, however it is usually a mixture of both.4 In deficiency, tears fail to be made and cannot 
complete lubrication. In evaporation, tears are lost and abnormal lipids levels exist.4,6 In either 
type, increased osmolarity of the tear film results in release of pro-inflammatory cytokines (IL-1, 
IL-6 and TNF-α),1 which activates sensory nerves and triggers dry eye symptoms.6 The poor 
quality of tears focuses light improperly on the retina and blurs the vision reversibly.6 Most 
patients suffer mild to moderate discomfort chronically.  
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An estimated 14.5% of adults in the United States suffer from dry eyes, including 17.9% of 
women and 10.5% of men affected.7 Up to 30% of Americans over the age of 50 are reportedly 
affected and the prevalence is expected to increase with the aging population.7 Post menopausal 
women are especially at risk due to changes in hormone levels.5 In addition, DES is now 
affecting younger generations due to constant computer use that reduces the frequency of 
blinking.4,6 Other risk factors include contact lens (CL) use, low humidity environments, 
previous eye surgery, presence of systemic disease and certain medications4,6 All of these factors 
have been known to reduce the quality and quantity of tears.6 
It’s estimated that the annual cost of managing dry eye in the U.S is $55 billion.8 No data 
is available on the number of healthcare visits for dry eyes annually. However, it is stated to be 
the most common reason for seeking eye care.7 Most patients present with non-specific irritative 
symptoms such as burning, pruritus, foreign body sensations, excessive tearing, blurry vision, 
photophobia and redness.6,7 Other complaints relate to vision impairment and include difficulty 
reading, driving or performing daily activities.4 Ultimately, quality of life can be significantly 
reduced in DES to a degree that has been reported to be equivalent to angina pectoris.7   
Artificial tears (AT’s), available over-the-counter, are the mainstay of treatment.6 They 
enhance the viscosity of tears and provide only short-term relief from irritation without 
addressing inflammation.4,6 Warm compresses are an option for extra support.4 First line medical 
therapies includes topical immunosuppressant drugs that reverse the inflammatory mechanism.4,6 
This includes Restasis® (cyclosporine emulsion) 0.05%, cytokine activation inhibitor and 
Xiidra® (lifitegrast solution) 5%, an integrin antagonist.4,6 Both products are expensive without 
insurance but can potentially offer long-term relief.4,6,7 Ultimately, for most patients, there is no 
permanent solution and treatment is long-term with a combination of methods.4,6,7 
	 	 Laureni,	Omega-3	in	Dry	Eyes,	5		
Omega-3 is a polyunsaturated fat essential for normal growth and development of the 
human body.4,9 Benefits in the eye include increased levels of fatty acids in secretions, which 
improves tear film quality and prevent evaporation, thus reducing DES symptoms.4,6 When 
digested omega-3 favors anti-inflammatory pathways via the blockade of cytokines and 
competitively inhibits pro-inflammatory pathways.1,2,7 Consuming cold-water fish (salmon, tuna 
and sardines) with high amounts of ω-3 helps raise levels in the body.9 However, fish have high 
mercury levels as well as other toxins and cannot be consumed in quantities that would benefit 
the eye without causing other health risks.1,9 
This method of treatment is being proposed because omega-3 supplements are marketed 
for and recommended by practitioners for DES but research has been inconsistent. Omega-3 is 
best absorbed by the human body in its natural triglyceride form, however, during manufacturing 
it gets converted into an ethyl ester via distillation, which is necessary for toxin elimination. 1,9 
Most omega-3 products are available in this poorly absorbed formula. Newer re-esterified 
formulas have been converted back into a triglyceride for better absorption. 2,9 In addition, it has 
been suggested that phospholipid form, as in krill oil, has even greater bioavailability. This paper 
will compare the three different types of omega-3 by measuring patient reported symptoms. 
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not daily 
supplementation with oral omega-3 fatty acids is effective in reducing the severity of dry eye 
symptoms in adult patients with clinically diagnosed DES.  It is hypothesized that daily intake is 
associated with an improvement in symptoms and result in a better quality of life.  
METHOD 
Three randomized controlled trials (double-blind, placebo-controlled) are reviewed in this 
paper that focused on a population of adult patients (18 -90 years old) with a history of DES. The 
	 	 Laureni,	Omega-3	in	Dry	Eyes,	6		
intervention of choice is daily oral supplementation with ω-3 fatty acids containing 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). The experimental groups 
received ω-3 fatty acids and are compared to the control groups who received a visually matched 
placebo. Outcome measured is the severity of dry eyes symptoms measured subjectively by each 
patient through a 12-item questionnaire, after a minimum of one month and maximum 12 weeks 
of treatment. Physical discomfort, visual impairment or environmental triggers were inquired 
about in the assessements.1,2,3 
The author of this paper performed the research as well as selected the articles for review 
by conducting searches on PubMed and Cochrane Library. Each of the three articles had been 
published data in peer-reviewed journals in the English language. The search criteria included 
‘Dry eye syndrome’ & ‘Omega-3 fatty acids’ as keywords. When selecting studies, the inclusion 
criteria consisted of studies that were RCT’s published between 2006 and 2016, studies that used 
a regimen of EPA and DHA omega-3 fatty acids in the experimental group and studies that used 
the OSDI questionnaire. Exclusion criteria were studies with participants under the age of 18, 
studies that allowed use of other therapies, and studies specific to CL use, computers or diseases. 
In each study, statistics were reported as the mean change in score (OSDI scale) from baseline at 
day one +/- standard error the mean (SEM), as well as in p-value for statistical significance 
(p<0.05).1,2,3 Treatment safety was based on the number of reported adverse events.  
Table 1: Demographics & Characteristics of Included Studies 
Study Type # 
Pts 
Age 
(yrs) 
Inclusion 
Criteria 
Exclusion Criteria W/D Interventions 
Deinema, 
20171 
RCT 60 ≥18 Mild-to-
moderate dry 
eye symptoms 
(OSDI score: 
18-65); Tear 
osmolarity of 
≥316 mOsm/L 
in at least one 
eye; IOP <21 
OU; BCVA 
≥20/40 OU 
 
Co-morbid ocular pathology; 
Uncontrolled systemic disease; 
Systemic disease contraindicating 
omega-3 supplements; Allergy to 
fish/seafood, nuts, oil or gelatin; Current 
use of oral ω-3 supplements; Contact 
lens use within one month or intended 
use over course of study; History of 
ocular surgery or trauma; Active ocular 
infection or allergy; Use of topical 
ocular medications (steroids, NSAIDs, 
or cyclosporine) and systemic anti-
coagulants in the 3 prior months; Use of 
6 5 capsules/day 
for 3 months of 
either:  
a) Krill oil: 945 
mg/day EPA & 
510 mg/day 
DHA. 
OR 
b) Fish oil: 1000 
mg/day EPA & 
500 mg/day 
DHA. Total 
1500mg daily. 
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any prescription or supplement that 
affect tear production or vision. 
Epitropoul
os, 20162 
RCT 122 21-86 
(>18) 
MGD stage 
1,2; Tear 
osmolarity of 
≥312 mOsm/L 
in at least one 
eye on 2 visits 
MGD stage 3; Use of topical 
cyclosporine 0.05%, corticosteroids, 
NSAIDs, glaucoma medication, or oral 
ω-3 fatty acids within 3 weeks of 
screening; (+) History of refractive 
surgery within 1 year; Use of systemic 
medication that affects ocular surface. 
17 4 softgels/day 
for 12 weeks:  
1680 mg/day 
EPA & 560 
mg/day DHA 
(re-esterified). 
Total 2240mg.  
Kangari, 
20133 
RCT 73 45-90  TBUT <10 
seconds in both 
eyes; No use of 
artificial tears 
for past 3 
months 
 
Active allergies or infection at ocular 
surface; Presence of pterygium or 
pinguecula; Use of topical steroidal, 
NSAID, glaucoma, or anti-allergy eye 
drop in past month; (+) History of 
refractive surgery, contact lens use, 
blood/coagulation disorder, gastric 
ulcer, or fish oil/gelatin allergy; Use of 
medication that interferes with tear 
production; (+) History of any surgery 
or use of ω-3 supplements in past 3 
months; Currently undergoing 
head/neck radiotherapy. 
9 2 capsules/day 
(AM & PM) for 
1 month: 360 
mg/day EPA & 
240 mg/day 
DHA. Total 
600mg daily. 
 
Abbreviations: Ocular Surface Disease Index (OSDI); Meibomian gland dysfunction (MGD); Tear breakup time (TBUT); 
Eicosapentaenoic acid (EPA); Docosahexaenoic acid (DHA); Non-steroidal anti-inflammatory drug (NSAID) 
OUTCOMES  
The Ocular Surface Disease Index (OSDI), (Allergan, Inc.), scale was used to measure 
subjective outcomes in all studies. This is a validated 12-item survey that ranks symptoms using 
a 5-point scale (0 = none of the time, 1 = some of the time, 2 = half the time, 3 = most of the 
time, 4 = all of the time). Each patient completed a questionnaire at every follow-up. The total 
score range is from 0 (none, no disability) to 100 (maximum, full disability) with higher values 
representing greater disability. It was important to calculate each subject’s average score per 
session as well as the change in scores between the first and the last day of studies.1,2,3 
RESULTS 
 
This paper investigates three randomized controlled trials (RCT’s) that assessed the 
efficacy of ω-3 fatty acid supplementation in the treatment of DES. Methods of data collection as 
well as inclusion and exclusion criteria are discussed above (see Table 1). All three studies 
randomized their subjects to either control or experimental treatments group(s), assignments to 
which the participants, clinicians and investigators were blind during allocation and throughout 
the studies. All three studies used a placebo that was visually comparable to the treatment 
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received by experimental group(s). Although the specific placebo varied among each study, ω-3 
regimens were also different. Treatment efficacy from all three studies was reported as 
continuous data that could not be converted to dichotomous data.1,2,3 Treatment safety is reported 
as numbers needed to harm (NNH) and was converted into dichotomous format. 
All three studies used the OSDI for symptom assessment as well as patients previously 
diagnosed with DES, which was of mild to moderate severity in Deinema et al (2017) and 
Epitropoulo et al (2016). In addition all groups in each study had similar OSDI scores at 
baseline. All three papers concluded that ω-3 does reduce the severity of DES symptoms, 
specific parameters are described below (table 2).1,2,3 
Table 2: Outcomes of Included Studies 
Study Duration # Participants 
(n) 
Significant 
Intervention 
Mean 
change from 
baseline 
score (scale 
of 100) 
p-value  95% CI 
Deinema, 
20171 
90 days 54 Krill oil 
(1500mg/day) 
-18.6+/-2.4 p = 0.02 N/A 
Epitropoulos, 
20162 
90 days 105 Re-esterified 
(2240mg/day) 
-17.0+/-2.6  p = 0.002 -12.0 (-19.4 to -4.5) 
Kangari, 
20133 
30 days 64 DHA & EPA 
(600mg/day) 
-9.4+/-0.6 P = 0.004 N/A 
30 days 64 Placebo +1.2+/-0.3 P = 0.049 Note: symptoms worsened 
 
Deinema et al (2017), is a double-masked, placebo-controlled study (table 3). It enrolled 
60 adult patients that were randomly assigned to one of three groups. Assessments occurred in 
four visits over 90 days for the 54 that completed the study. EPA/DHA is a phospholipid in krill 
oil and is a triglyceride in fish oil, the later being studied more frequently. The placebo was a 
1500mg dose of oleic acid (olive oil). While CL use was forbidden, AT use was permitted 
throughout the study. In addition, subjects were asked about dietary changes at each visit. The 
outcome measured was dry eye symptoms severity on the OSDI scale. Factors affecting the 
outcome include the small size of participants (n=54), recruitment from only one treatment 
center, high 1500mg dosing, and type of lipid received by participants.  
In patients taking krill oil supplementation, dry eye symptoms improved 18.6 points over 
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three months as measured by OSDI scores. Meanwhile the placebo group reported a 10.5+/-3.3 
point improvement. This represents a reduction from baseline, in other words, an improvement 
of symptoms for the krill oil group (mean change in baseline score = -18.6+/-2.4, p = 0.02).  
Compared to placebo, only the krill oil group score was statistically significant at day 90 
relative to day 1. The outcome was not significant and therefore not reported for fish oil. This 
means that ω-3 in phospholipid form of krill oil may offer superior benefits for DES symptoms 
compared to triglyceride form of fish oil. Outcomes were not significant for any group at the 2nd 
or 3rd follow-up and not reported.1 However, data trends showed improvements for each 
throughout the study, suggesting greater outcome with longer duration of therapy. 
Table 3: Treatment Effect in Deinema et al (2017)1   (Scores at day 30,60, 90 not reported) 
 Baseline Mean change from baseline +/- SEM (scale of 100) 
Krill Oil (n=18) 30.5 +/- 2.4 -18.6+/-2.4, p=0.02 
Fish Oil (n=19 36 +/- 3.4 Not reported 
Placebo (n=17) 31.7 +/- 2.6 -10.5 +/-3.3 
 
Epitropoulo et al (2016), is a multi-centered, double-masked, placebo-controlled study 
(table 4) that enrolled 122 adult patients that were randomly assigned to group 1 or 2. For the 
105 participants that completed the study, assessments took place in 3 visits over 90 days. The 
EPA/DHA provided was in re-esterified form. The placebo was a dose of linoleic acid (safflower 
oil), a ω-6 fatty acid. CL and AT use was allowed except before visits for 12 and 2 hours, 
respectively. Subjects kept daily food diaries and dietary changes were not allowed. The 
outcome was dry eye symptoms severity on the OSDI scale. Factors affecting the outcome 
include the use of re-esterified ω-3, the female majority of participants, high dosing with 2240mg 
daily. In addition, the choice of ω-6 as a placebo could worsen inflammation as it has been 
shown to have this effect in the body, which is opposite to that of omega-3. 
In the experimental group, dry eye symptoms improved 17 points over three months as 
measured by OSDI scores. Meanwhile the control group had only 5.0+/-2.7 point improvement. 
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These values represent a reduction from baseline, in other words, an improvement of symptoms 
with treatment (mean change in baseline score = -17.0+/-2.6, p = 0.002, CI = -19.4 to -4.5).  
Compared to the control, the score of the treatment group was statistically significant at 
12 weeks relative to day 1. This means that the re-esterified omega-3 benefits DES symptoms, 
although it is uncertain whether it is superior to the usual triglyceride form. Outcomes were not 
significant at 6-weeks, although both groups had less symptoms at this visit.2 
Table 4: Treatment Effect in Epitropoulo et al (2016)2  Mean change from baseline +/- SEM (scale of 100) 
 Baseline 6 weeks Mean Change 95% CI 12 weeks Mean Change 95% CI 
Omega-3 
(n=54) 
32.4+/-19.2 21.0+/-14.4 -11.4+/-2.6 -4.0(-11.2 
to 3.3); 
p=0.285 
15.5+/-11.0 -17.0+/-2.6 -12.0 (-19.4 to -
4.5); p=0.002 
Placebo 
(n=51) 
27.1+/-22.9 19.6+/-17.0 -7.4+/-2.6 22.0+/-19.3 -5.0+/-2.7 
 
Kangari et al (2013), is a double-masked, placebo-controlled study (table 5). It randomly 
assigned 73 patients, ages 45-90, to group 1 or 2. Only 64 completed the study and attended each 
of two visits within one month. The specific type of EPA/DHA provided was not reported. The 
placebo was a medium chain triglyceride. CL and AT use was forbidden throughout the study.  
The outcome measured was dry eye symptom severity, on the OSDI scale, at day 30. Factors 
affecting the study outcome include the small number of participants (n=64), recruitment from 
only one center, small dosing of 600mg/day, the short study duration compared to others, lack of 
dietary control over the subjects, and older ages of patients who are at higher risk for DES. The 
paper did not mention criteria for disease severity during enrollment.  
In the treatment group, dry eye symptoms improved 9.4 points over three months as 
measured by OSDI scores. This represents a reduction from baseline, in other words, an 
improvement of symptoms by 26% (mean change from baseline = -9.4+/-0.6; p = 0.004). The 
treatment group’s score was statistically significant at day 30 relative to day one. Surprisingly, 
the control had a 1.2+/-0.3 point decline (p=0.049), meaning that symptoms worsened by 4%. 
This suggests that not having the treatment was powerful enough to overcome any placebo effect 
that occurs when taking the treatment alone causes positive outcomes.3 
	 	 Laureni,	Omega-3	in	Dry	Eyes,	11		
Table 5: Treatment Effect in Kangari et al (2013)3 
 Baseline Score Day 30 Score Mean change from baseline +/- 
SEM (scale of 100) 
Omega-3 (n=31) 38.7+/-16.5 29.3+/-15.9 -9.4+/-0.6 (p = 0.004) 
Placebo (n=33) 36.4+/-13.8 37.6+/-13.5 +1.2+/-0.3 (p = 0.049) 
 
This discussion pertains to 3 different RCT studies that each compared experimental 
treatment by ω-3 (EPA & DHA) with placebos. Epitropoulos et al (2016) and Kangari et al 
(2013) each evaluated a single type of omega-3, however, two different forms (krill and fish oil) 
were assessed in Deinema et al (2017). Compliance was only assessed in Deinema et al (2017), 
Epitropoulos et al (2016) by count of returned medication containers. Epitropoulos et al (2016) 
sent daily medication remainders to their subjects via text, which most likely increased their 
compliance and improved their data.  
Each study took place at ophthalmology clinics in symptomatic patients having a history 
of clinically diagnosed DES. Deinema et al (2017) was conducted in Melbourne, Australia using 
mild-moderate DES patients. Epitropoulos et al (2016) recruited patients with stage 1 or 2 MGD 
from various U.S. clinics. Kangari et al (2013) used a private clinic in Tehran, Iran. Outcomes 
specific to race, diet and climate cannot be accounted for in this paper considering each study 
was conducted on a different continent from the others. 
Analysis of the OSDI scores from the treatment groups was compared to controls in each 
of the three studies. In Deinema et al (2017), each treatment under investigation appeared to 
show improvement but statistically only the outcome of krill oil was significant at 90 days. In 
addition, both Epitropoulos et al (2016) and Kangari et al (2013) reported significant treatment 
effect at 90 and 30 days, respectively. The former also reported worsening of symptoms for the 
control suggesting a preventative effect by ω-3. 
In Deinema et al (2017), the number of reported adverse events was used for assessment 
of treatment safety. From this data, the risk of harm was calculated and reported in numbers 
needed to harm (NNH). Formulas and calculations can be found in table 6. A NNH of 4 means 
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that for every 4 people treated with fish oil (3 people for krill oil), one person has a bad event. 
While 53 events were reported, 51 of the events were mild (well-tolerated), 2 were moderate 
(interfered with activity) and none were severe (life-threatening). The most common were colds 
(24.5%), sore throat (11.3%), headache (13.2%), GI events (nausea, bloating, heartburn; 11.3%) 
and remaining 39.6% not associated with treatment. Ultimately, while side effects are noticeable, 
omega-3 has low toxicity and remains a feasible treatment option. 
Table 6: Adverse Events (NNH) of Treatment in Deinema et al (2017) 
 # of 
events 
CER (control event 
rate) = events/total # 
subjects 
EER (experimental 
event rate) = 
events/total # subjects 
RRI (relative risk 
increase) = (EER-
CER)/CER 
ARI (absolute risk 
increase) = EER-
CER 
NNH (numbers 
needed to harm) = 
1/ARI 
Placeb
o, 17 
20 1.2% N/A N/A N/A N/A 
Fish 
Oil, 18 
19 1.2% 1.0% 0.2% 0.2% 4 
Krill 
Oil, 15 
18 1.2% 0.8% 0.3% 0.5% 3 
 
DISCUSSION 
For many decades, the potential health benefits of ω-3 consumption have been the focus 
of a multitude of scientific research areas. Despite speculation, omega-3 has not been associated 
with a rate reduction in cardiovascular events,9 risk reduction in cancer5 nor in the prevention of 
Alzheimer’s disease.5 It is however, approved in prescription for severe (≥500 mg/dL) 
hypertriglyceridemia, serving as secondary prevention in coronary heart disease (CHD).9 
Furthermore, investigation in depressive disorders continues.5,6 Ultimately, the exact role of 
omega-3 on inflammatory processes in the human body must be further explored. 
In Deinema et al (2017) and Epitropoulos et al (2016), subjects younger than 18 were 
excluded, as they are unlikely to be affected so unlikely to seek treatment. However, Kangari et 
al (2013) excluded patients under the age of 45, which means this study focused on an older 
population who are more likely to be afflicted. 1,2,3 Meanwhile none of the studies allowed 
participation by patients with ocular or systemic diseases that, compared to the general adult 
population, are more prone to DES and more likely to present with it clinically.1,2,3 
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Significant data from each of the studies was collected at a specified point in time during 
ω-3 intervention. The most dramatic improvement in symptoms occurred at three months as in 
Deinema et al (2017) with krill oil (18.6 point score reduction). This is compared to 3 months in 
Epitropoulos et al (2016) with re-esterified ω-3 (17.0 point reduction), and one month in Kangari 
et al (2013) with unspecified low-dose DHA/EPA (9.4 point reduction). Point reduction means 
that symptoms improved and represents a positive outcome. The author’s decision to restrict 
article selection to studies using OSDI may have placed data in favor of this hypothesis.  
CONCLUSION 
It can be concluded that daily ω-3 fatty acid supplementation is effective for reducing the 
severity of dry eye syndrome in adults, especially those with mild-moderate disease, after 90 
days of use. Based on the data presented in this paper, krill oil (>1500mg) offers the greatest 
treatment effect but also causes the most side effects. Re-esterified formulas (2240mg) are the 
second most effective. The longer the treatment, the better the symptoms.  This is attributed to 
the anti-inflammatory effect of ω-3 that has been demonstrated in prior studies.1,5 Ultimately, 
daily ω-3 fatty acid supplementation has capacity to improve quality of life for DES patients.  
While the type, the dose, and the duration of omega-3 treatment all influential the 
outcome of treatment, however additional trials are needed to clarify which factor is most 
important. Currently studies are being conducted to assess the treatment effect of ω-3 along with 
ω-6 supplementation.1,2 Meanwhile, future studies are necessary to evaluate ω-3 in combination 
with and in contrast to the first line therapies including Restasis and Xiidra. In addition, is also 
important to compare the side effect profile of re-esterified oils to krill oils. Overall, a 
multicenter clinical trial with an increased number of participants and longer treatment duration 
must take place in order to assess the efficacy and safety of krill oil and re-esterified ω-3 fatty 
acids long-term. 
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